PRIMARY STUDY

Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212–2 in renal cell carcinoma.

Key Findings:  The study shows the involvement of CB2 receptor agonism via WIN 55,212–2 inhibits renal cell carcinoma in vitro.

Type of Study:  Laboratory Study

Study Result:  Positive

Study Location(s):  Canada, Poland

Year of Pub:  2018


Cannabinoids Studied:  AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Synthetic Cannabinoid (unspecified)

Phytocannabinoid Source:  Not Applicable

Receptors Studied:  CB1, CB2

Route of Administration:  In vitro



Link to study